HK1224296A1 - 布羅莫結構域抑制劑 - Google Patents

布羅莫結構域抑制劑

Info

Publication number: HK1224296A1
Authority: HK; Hong Kong
Prior art keywords: bromodomain inhibitors; bromodomain; inhibitors
Prior art date: 2013-06-28

Application number

HK16112709.9A

Other languages

English (en)

Inventor

Le Wang

Yujia Dai

James HOLMS

Dachun Liu

William Mcclellan

Keith MCDANIEL

Lisa Hasvold

Steven D Fidanze

George SHEPPARD

Jasmina Marjanovic

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-28

Filing date

2016-11-04

Publication date

2017-08-18

2016-11-04 Application filed by Abbvie Inc filed Critical Abbvie Inc

2017-08-18 Publication of HK1224296A1 publication Critical patent/HK1224296A1/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Neurology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Virology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Transplantation (AREA)

HK16112709.9A 2013-06-28 2016-11-04 布羅莫結構域抑制劑 HK1224296A1 (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361840559P	2013-06-28	2013-06-28
PCT/CN2014/077395 WO2014206150A1 (en)	2013-06-28	2014-05-13	Bromodomain inhibitors
PCT/CN2014/080991 WO2014206345A1 (en)	2013-06-28	2014-06-27	Bromodomain inhibitors

Publications (1)

Publication Number	Publication Date
HK1224296A1 true HK1224296A1 (zh)	2017-08-18

Family

ID=52140993

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
HK16111612.7A HK1223364A1 (zh)	2013-06-28	2016-10-06	布羅莫結構域抑制劑
HK16111608.3A HK1223363A1 (zh)	2013-06-28	2016-10-06	布羅莫結構域抑制劑
HK16112709.9A HK1224296A1 (zh)	2013-06-28	2016-11-04	布羅莫結構域抑制劑
HK16112710.6A HK1224297A1 (zh)	2013-06-28	2016-11-04	布羅莫結構域抑制劑

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
HK16111612.7A HK1223364A1 (zh)	2013-06-28	2016-10-06	布羅莫結構域抑制劑
HK16111608.3A HK1223363A1 (zh)	2013-06-28	2016-10-06	布羅莫結構域抑制劑

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK16112710.6A HK1224297A1 (zh)	2013-06-28	2016-11-04	布羅莫結構域抑制劑

Country Status (23)

Country	Link
US (3)	US10131657B2 (zh)
EP (2)	EP3013828A4 (zh)
JP (2)	JP2016525503A (zh)
KR (2)	KR20160027062A (zh)
CN (2)	CN105518007A (zh)
AR (1)	AR096757A1 (zh)
AU (2)	AU2014303193A1 (zh)
BR (2)	BR112015032710A2 (zh)
CA (2)	CA2916542A1 (zh)
CL (1)	CL2015003731A1 (zh)
CR (1)	CR20160035A (zh)
DO (2)	DOP2015000305A (zh)
HK (4)	HK1223364A1 (zh)
IL (2)	IL243371A0 (zh)
MX (2)	MX2015017963A (zh)
NZ (1)	NZ631062A (zh)
PE (2)	PE20160540A1 (zh)
PH (2)	PH12015502852A1 (zh)
RU (2)	RU2016102647A (zh)
SG (2)	SG11201510678TA (zh)
TW (1)	TW201536780A (zh)
UY (1)	UY35633A (zh)
WO (2)	WO2014206150A1 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013097052A1 (en) *	2011-12-30	2013-07-04	Abbott Laboratories	Bromodomain inhibitors
WO2014143768A1 (en)	2013-03-15	2014-09-18	Incyte Corporation	Tricyclic heterocycles as bet protein inhibitors
PE20160540A1 (es) *	2013-06-28	2016-06-11	Abbvie Inc	Inhibidores de bromodominios
ES2635560T3 (es)	2013-07-08	2017-10-04	Incyte Holdings Corporation	Heterociclos tricíclicos como inhibidores de la proteína NET
HUE048371T2 (hu)	2013-10-18	2020-07-28	Celgene Quanticel Res Inc	Bromodomén inhibitorok
US9399640B2 (en)	2013-11-26	2016-07-26	Incyte Corporation	Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en)	2013-12-19	2016-04-12	Incyte Corporation	Tricyclic heterocycles as BET protein inhibitors
WO2015164480A1 (en)	2014-04-23	2015-10-29	Incyte Corporation	1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
JP6599979B2 (ja)	2014-09-15	2019-10-30	インサイト・コーポレイション	Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
MA40943A (fr)	2014-11-10	2017-09-19	Constellation Pharmaceuticals Inc	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr)	2014-11-10	2017-09-19	Constellation Pharmaceuticals Inc	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
WO2016077375A1 (en)	2014-11-10	2016-05-19	Genentech, Inc.	Bromodomain inhibitors and uses thereof
JP6709792B2 (ja)	2015-01-29	2020-06-17	ジェネンテック，インコーポレイテッド	治療用化合物およびその使用
GB201504694D0 (en)	2015-03-19	2015-05-06	Glaxosmithkline Ip Dev Ltd	Covalent conjugates
AR106520A1 (es)	2015-10-29	2018-01-24	Incyte Corp	Forma sólida amorfa de un inhibidor de proteína bet
TW202304907A (zh) *	2016-04-15	2023-02-01	美商艾伯維有限公司	溴域抑制劑
CN105924841A (zh) *	2016-06-02	2016-09-07	扬州兰都塑料科技有限公司	一种力学性能改善的电力电缆的制备方法
CN105924842A (zh) *	2016-06-02	2016-09-07	扬州兰都塑料科技有限公司	一种力学性能改善的电力电缆
CN105924671A (zh) *	2016-06-02	2016-09-07	扬州兰都塑料科技有限公司	一种电力电缆用增韧剂
JP7096170B2 (ja)	2016-06-20	2022-07-05	インサイト・コーポレイション	Ｂｅｔ阻害剤の結晶固体形態
CN108069958A (zh) *	2016-11-10	2018-05-25	凯惠科技发展(上海)有限公司	一种含氮杂环类化合物、其制备方法、药物组合物及应用
TW201825490A (zh) *	2017-01-11	2018-07-16	大陸商江蘇豪森藥業集團有限公司	吡咯並［２，３－ｃ］吡啶類衍生物、其製備方法及其在醫藥上的應用
CN109384784B (zh) *	2017-08-10	2021-01-12	浙江海正药业股份有限公司	磺酰胺类衍生物、其制备方法及其在医药上的用途
KR102026243B1 (ko) *	2018-01-19	2019-09-27	연세대학교 산학협력단	백혈병 치료용 약학적 조성물
WO2019184919A1 (zh) *	2018-03-27	2019-10-03	成都海创药业有限公司	一种含有金刚烷的化合物及其在治疗癌症中的用途
BR112020019824A2 (pt) *	2018-03-29	2021-01-05	Board Of Regents, The University Of Texas System	Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica, método de inibição de cbp, método de inibição de p300, método de tratamento de uma doença mediada por cbp, método de tratamento de uma doença mediada por p300 e método para alcançar um efeito em um paciente
US10442799B1 (en)	2018-04-07	2019-10-15	Fuqiang Ruan	Heterocyclic compounds and uses thereof
WO2020020288A1 (zh)	2018-07-25	2020-01-30	正大天晴药业集团股份有限公司	作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
CN110776508B (zh) *	2018-07-27	2021-07-16	海创药业股份有限公司	一种brd4抑制剂及其制备方法和用途
AU2019372121A1 (en)	2018-10-30	2021-05-27	Nuvation Bio Inc.	Heterocyclic compounds as BET inhibitors
WO2020132004A1 (en) *	2018-12-20	2020-06-25	Saint Louis University	Bet inhibitors for modulating dux4 expression in fshd
CA3133131A1 (en) *	2019-03-17	2020-09-24	Shanghai Ringene Biopharma Co., Ltd.	Pyrrole amidopyridone compound, preparation method therefor and use thereof
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
WO2020253711A1 (zh) *	2019-06-17	2020-12-24	中国科学院上海药物研究所	一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
JP7465945B2 (ja)	2019-07-02	2024-04-11	ニューベイション・バイオ・インコーポレイテッド	Ｂｅｔ阻害剤としてのヘテロ環式化合物
WO2021065980A1 (ja)	2019-09-30	2021-04-08	協和キリン株式会社	Ｂｅｔ分解剤
CN112625036A (zh) *	2019-10-08	2021-04-09	上海海和药物研究开发股份有限公司	一类具有brd4抑制活性的化合物、其制备方法及用途
CN113387879B (zh) *	2020-03-14	2023-05-30	成都先导药物开发股份有限公司	一种胺类衍生物、其制备方法及其在医药上的应用
BR112022020283A2 (pt) *	2020-04-08	2022-12-06	Aptabio Therapeutics Inc	Agente para tratamento de lesão renal aguda induzida por contraste
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
GB202016977D0 (en)	2020-10-26	2020-12-09	In4Derm Ltd	Compounds
AU2022303310A1 (en)	2021-06-29	2024-02-08	Tay Therapeutics Limited	Pyrrolopyridone derivatives useful in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW263498B (zh)	1993-11-10	1995-11-21	Takeda Pharm Industry Co Ltd
JPH08337583A (ja)	1995-04-13	1996-12-24	Takeda Chem Ind Ltd	複素環化合物およびその製造法
US6271380B1 (en) *	1998-12-30	2001-08-07	Dupont Pharmaceuticals Company	1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
EP1887008B1 (en)	2005-05-30	2021-04-21	Mitsubishi Tanabe Pharma Corporation	Thienotriazolodiazepine compound and a medicinal use thereof
GB0919434D0 (en) *	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds
WO2011143651A1 (en)	2010-05-14	2011-11-17	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating metabolism
EP2571503B1 (en) *	2010-05-14	2015-01-07	Dana-Farber Cancer Institute, Inc.	Compositions and their use in treating neoplasia, inflammatory disease and other disorders
WO2013097052A1 (en) *	2011-12-30	2013-07-04	Abbott Laboratories	Bromodomain inhibitors
PE20160540A1 (es) *	2013-06-28	2016-06-11	Abbvie Inc	Inhibidores de bromodominios

2014
- 2014-05-13 PE PE2015002662A patent/PE20160540A1/es not_active Application Discontinuation
- 2014-05-13 EP EP14818258.7A patent/EP3013828A4/en not_active Withdrawn
- 2014-05-13 RU RU2016102647A patent/RU2016102647A/ru not_active Application Discontinuation
- 2014-05-13 CN CN201480047385.5A patent/CN105518007A/zh active Pending
- 2014-05-13 KR KR1020167002406A patent/KR20160027062A/ko not_active Withdrawn
- 2014-05-13 MX MX2015017963A patent/MX2015017963A/es unknown
- 2014-05-13 AU AU2014303193A patent/AU2014303193A1/en not_active Abandoned
- 2014-05-13 US US14/392,200 patent/US10131657B2/en active Active
- 2014-05-13 WO PCT/CN2014/077395 patent/WO2014206150A1/en active Application Filing
- 2014-05-13 JP JP2016522200A patent/JP2016525503A/ja active Pending
- 2014-05-13 CA CA2916542A patent/CA2916542A1/en not_active Abandoned
- 2014-05-13 SG SG11201510678TA patent/SG11201510678TA/en unknown
- 2014-05-13 BR BR112015032710A patent/BR112015032710A2/pt not_active IP Right Cessation
- 2014-06-26 AR ARP140102430A patent/AR096757A1/es unknown
- 2014-06-27 CA CA2916744A patent/CA2916744A1/en not_active Abandoned
- 2014-06-27 UY UY0001035633A patent/UY35633A/es not_active Application Discontinuation
- 2014-06-27 TW TW103122420A patent/TW201536780A/zh unknown
- 2014-06-27 MX MX2015017964A patent/MX2015017964A/es unknown
- 2014-06-27 BR BR112015032693A patent/BR112015032693A2/pt active Search and Examination
- 2014-06-27 JP JP2016522234A patent/JP2016523271A/ja active Pending
- 2014-06-27 SG SG11201510677VA patent/SG11201510677VA/en unknown
- 2014-06-27 KR KR1020167002583A patent/KR20160027107A/ko not_active Withdrawn
- 2014-06-27 RU RU2016102648A patent/RU2016102648A/ru not_active Application Discontinuation
- 2014-06-27 CN CN201480047377.0A patent/CN105531273A/zh active Pending
- 2014-06-27 PE PE2015002684A patent/PE20160200A1/es not_active Application Discontinuation
- 2014-06-27 EP EP14818239.7A patent/EP3013827A4/en not_active Withdrawn
- 2014-06-27 AU AU2014301818A patent/AU2014301818A1/en not_active Abandoned
- 2014-06-27 US US14/392,201 patent/US9957263B2/en active Active
- 2014-06-27 NZ NZ631062A patent/NZ631062A/en not_active IP Right Cessation
- 2014-06-27 WO PCT/CN2014/080991 patent/WO2014206345A1/en active Application Filing
2015
- 2015-12-22 PH PH12015502852A patent/PH12015502852A1/en unknown
- 2015-12-22 DO DO2015000305A patent/DOP2015000305A/es unknown
- 2015-12-24 CL CL2015003731A patent/CL2015003731A1/es unknown
- 2015-12-27 IL IL243371A patent/IL243371A0/en unknown
- 2015-12-27 IL IL243372A patent/IL243372A0/en unknown
- 2015-12-28 DO DO2015000308A patent/DOP2015000308A/es unknown
2016
- 2016-01-04 PH PH12016500024A patent/PH12016500024A1/en unknown
- 2016-01-19 CR CR20160035A patent/CR20160035A/es unknown
- 2016-10-06 HK HK16111612.7A patent/HK1223364A1/zh unknown
- 2016-10-06 HK HK16111608.3A patent/HK1223363A1/zh unknown
- 2016-11-04 HK HK16112709.9A patent/HK1224296A1/zh unknown
- 2016-11-04 HK HK16112710.6A patent/HK1224297A1/zh unknown
2018
- 2018-11-16 US US16/192,927 patent/US20190084981A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3013828A4 (en)	2016-11-23
IL243371A0 (en)	2016-02-29
JP2016525503A (ja)	2016-08-25
AU2014301818A1 (en)	2016-01-28
HK1223363A1 (zh)	2017-07-28
CA2916744A1 (en)	2014-12-31
RU2016102647A (ru)	2017-08-01
NZ631062A (en)	2018-03-23
TW201536780A (zh)	2015-10-01
JP2016523271A (ja)	2016-08-08
AU2014303193A1 (en)	2016-01-28
PE20160200A1 (es)	2016-05-21
CA2916542A1 (en)	2014-12-31
US20160272630A1 (en)	2016-09-22
SG11201510677VA (en)	2016-01-28
US9957263B2 (en)	2018-05-01
US20160185769A1 (en)	2016-06-30
MX2015017964A (es)	2017-02-15
RU2016102648A (ru)	2017-08-02
RU2016102647A3 (zh)	2018-03-30
IL243372A0 (en)	2016-02-29
CN105518007A (zh)	2016-04-20
US20190084981A1 (en)	2019-03-21
WO2014206150A1 (en)	2014-12-31
UY35633A (es)	2014-10-31
DOP2015000305A (es)	2016-01-31
CL2015003731A1 (es)	2016-07-29
SG11201510678TA (en)	2016-01-28
KR20160027107A (ko)	2016-03-09
CR20160035A (es)	2016-04-22
MX2015017963A (es)	2016-11-10
KR20160027062A (ko)	2016-03-09
AR096757A1 (es)	2016-02-03
EP3013827A4 (en)	2016-11-23
HK1223364A1 (zh)	2017-07-28
RU2016102648A3 (zh)	2018-04-26
WO2014206345A1 (en)	2014-12-31
BR112015032710A2 (pt)	2017-07-25
US10131657B2 (en)	2018-11-20
PH12015502852A1 (en)	2016-03-21
EP3013828A1 (en)	2016-05-04
EP3013827A1 (en)	2016-05-04
HK1224297A1 (zh)	2017-08-18
BR112015032693A2 (pt)	2017-07-25
DOP2015000308A (es)	2016-03-15
PE20160540A1 (es)	2016-06-11
CN105531273A (zh)	2016-04-27
PH12016500024A1 (en)	2016-03-28

Publication	Publication Date	Title
IL256946B (en)	2019-02-28	Bromodomain inhibitors
HK1224296A1 (zh)	2017-08-18	布羅莫結構域抑制劑
ZA201506575B (en)	2019-05-29	Dihydro-pyrrolopyridinone bromodomain inhibitors
HK1224298A1 (zh)	2017-08-18	晶體溴結構域抑制劑
HK1217102A1 (zh)	2016-12-23	四環布羅莫結構域抑制劑
EP3080132A4 (en)	2017-08-02	Bromodomain inhibitors